Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Hepatitis Therapeutics Market?

The size of the hepatitis therapeutics market has consistently expanded over the recent years. The market is projected to increase from $18.66 billion in 2024 to $19.08 billion in 2025, boasting a compound annual growth rate (CAGR) of 2.2%. This growth witnessed in the historical period is due to factors such as the development of vaccines, antiviral medications, initiatives in public health, research funding, and emerging therapies.

The market size for hepatitis therapeutics is projected to experience consistent expansion in the upcoming years, escalating to a worth of “$22.32 billion in 2029 with a compound annual growth rate (CAGR) of 4.0%. The anticipated growth during the forecast period is ascribed to ongoing research and development, global healthcare drives, changes in patient care, government schemes, and an increase in disease awareness. Key trends to watch during the projection period are patient backing and support, persistent scrutiny and follow-up, healthcare fairness, telehealth and remote care, and an emphasis on hepatitis C eradication.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

What Market Forces Are Contributing To The Growth Of The Hepatitis Therapeutics Market?

The global increase in hepatitis infection is predicted to foster the growth of the hepatitis therapeutic market. The infection surge can be attributed to limited healthcare access and vaccinations, a spike in intravenous drug use, unsafe practices for blood transfusion, and substandard sanitation and hygiene conditions in certain global regions. For example, the World Health Organization (WHO), a public health agency of the United Nations based in the US, reported in April 2022 that at least 169 cases of acute hepatitis of unknown origin were documented from 11 countries. Furthermore, 350 million individuals across the globe are suffering from viral hepatitis B or C, but the majority still lack access to testing and treatment. As a result, the growth of hepatitis infection contributes to the expansion of the hepatitis therapeutics market.

Which Segment Accounts For The Largest Share In The Hepatitis Therapeutics Market?

The hepatitis therapeutics market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Drug Class: Oral Antivirals, Immune Modulators

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)

2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines

3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies

4) By Other Disease Types: Hepatitis D, Hepatitis E, Other Viral Hepatitis Infections

Which Long-Term Trends Will Play A Crucial Role In The Hepatitis Therapeutics Market?

Product enhancements have emerged as the leading trend making waves in the hepatitis therapeutics market. Pioneering firms in the hepatitis therapeutics market are rolling out fresh products to maintain their market presence. For example, in November 2022, Gilead Sciences, Inc., a biopharmaceutical company based in US attained FDA approval for a medication namely Vemlidy (tenofovir alafenamide) purpose-built for treating pediatric patients affected by chronic hepatitis B virus infection. Vemlidy, a designated prodrug of tenofovir, achieved FDA’s endorsement in 2016 for being a day-to-day treatment for individuals battling chronic hepatitis B virus (HBV) infection, as well as compensated liver ailment. The American Liver Foundation’s guidelines categorize it as a favored or frontline treatment for individuals having chronic HBV alongside compensated liver disease.

Who Are The Dominant Players In The Hepatitis Therapeutics Market Today?

Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

What Regional Factors Are Accelerating Growth In The Hepatitis Therapeutics Market?

North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9956&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model